8-K: Tevogen Bio Enters Agreement for Cell Therapy Production Facility

Tevogen Bio finalizes an agreement with CD 8 Technology Services LLC to develop a turn-key facility for in-house cell therapy production.

Summary

• Tevogen Bio Holdings Inc. has entered into a Master Services and Facilities Agreement with CD 8 Technology Services LLC to gain access to specialized manufacturing facilities and operational services for cell therapy production.
• The agreement aims to provide Tevogen with in-house pre-clinical research and GMP cell therapy production capabilities.
• The specific details of the facilities and services, including scope of work, costs, and timelines, will be defined in future project work orders.
• The agreement has an initial term of 12 months and will automatically renew for additional 12-month periods unless terminated.
• CD8 is associated with Dr. Manmohan Patel, who owns more than 5% of Tevogen's common stock.
• Tevogen believes this agreement will help overcome capital barriers to building GMP capabilities at scale and aligns with previously announced topline forecasts.

Sentiment

Score: 7

Explanation: The announcement is positive as it secures manufacturing capabilities, but the forward-looking statements include risks related to capital raising and other uncertainties.

Positives

• The agreement provides Tevogen Bio with in-house cell therapy production capabilities.
• It is expected to accelerate development timelines, maintain operational agility, and control costs.
• The agreement formalizes a previously announced letter of intent.
• Tevogen believes this agreement should allow the Company to overcome significant capital barriers of entry that are typically faced in building GMP capabilities at scale.

Risks

• Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.
• Changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes, could impact results.
• Changes in domestic and global general economic conditions could impact results.
• Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations.
• Tevogen may not be able to develop and maintain effective internal controls.
• The failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities could impact results.
• Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services.
• There are risks related to the ability to develop, license or acquire new therapeutics.
• There is a risk of regulatory lawsuits or proceedings relating to Tevogen's business.
• Uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials could impact results.
• There are risks related to regulatory review, approval and commercial development.
• There are risks associated with intellectual property protection.
• Tevogen has a limited operating history.

Future Outlook

Tevogen expects the agreement to support the advancement of its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics and aligns with previously announced topline forecasts.

Management Comments

• Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, commented that this milestone represents a significant step forward in Tevogen Bio's infrastructure expansion to support the advancement of its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics.
• Ryan Saadi also stated that they are exploring additional ways to recognize their real, long-term shareholders.

Industry Context

The agreement reflects a trend in the biopharmaceutical industry towards companies seeking greater control over their manufacturing processes, particularly for cell therapies, to reduce costs and accelerate development.

Comparison to Industry Standards

• Many cell therapy companies, such as Novartis and Gilead (through its acquisition of Kite Pharma), have invested heavily in their own manufacturing facilities to ensure product quality and supply chain control.
• Tevogen's approach of partnering with CD8 Technology Services to develop a turn-key facility is a less capital-intensive approach compared to building a facility from scratch, which can cost hundreds of millions of dollars.
• The 12-month initial term with automatic renewal is a common structure for service agreements in the biopharmaceutical industry.

Related Party Transactions

• CD8 is associated with Dr. Manmohan Patel, who beneficially owns more than 5% of Tevogen's common stock.

Stakeholder Impact

• Shareholders may view the agreement positively as it supports long-term growth and operational efficiency.
• Employees may benefit from the expansion of facilities and increased production capabilities.
• Patients may benefit from accelerated development timelines and increased access to cell therapy products.

Next Steps

• Specific details of the facility and related services, including scope of work, costs, and timelines, will be set out in one or more future work orders.
• Tevogen Bio will provide the primary staff and operations for the facility.

Key Dates

Keywords

cell therapy, manufacturing, GMP, Tevogen Bio, CD8 Technology Services, agreement, production facility